(Q36556502)

14 August 2017

1 reference

title

Loss of antibodies and response to (re-)vaccination in children after treatment for acute lymphocytic leukemia: a systematic review (English)

1 reference

acute lymphocytic leukemia

14 August 2017

0 references

1 reference

1 reference

1 reference

0 references

Rovers MM

3

0 references

author name string

van Tilburg CM

1

1 reference

14 August 2017

Sanders EA

2

1 reference

14 August 2017

Wolfs TF

4

1 reference

14 August 2017

Bierings MB

5

1 reference

14 August 2017

3 August 2006

1 reference

14 August 2017

1 reference

14 August 2017

20

1 reference

14 August 2017

10

1 reference

14 August 2017

1717-1722

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404326

14 August 2017

0 references

cites work

Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

Treatment of acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

Immune recovery in children with malignancy after cessation of chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

Immune reconstitution after childhood acute lymphoblastic leukemia is most severely affected in the high risk group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

Intensive treatment for childhood acute lymphoblastic leukemia reduces immune responses to diphtheria, tetanus, and Haemophilus influenzae type b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

Humoral immunity in pediatric patients with acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

Immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in children with sickle hemoglobinopathy or malignancies, and after systemic Haemophilus influenzae type b infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

Immunity against vaccine-preventable potentially neurotropic diseases in children treated for malignant brain tumours with HIT-91 chemo- and radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

Antibody titers and immune response to diphtheria-tetanus-pertussis and measles-mumps-rubella vaccination in children treated for acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

Immunodeficiency in children with acute lymphoblastic leukemia after completion of modern aggressive chemotherapeutic regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

Therapy-induced alterations in host defense in children receiving therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

Active immunization of children with leukemia and other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

Re-immunisation schedule in leukaemic children after intensive chemotherapy: a possible strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

Probable Inference, the Law of Succession, and Statistical Inference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

Acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Causes of death--other than progressive leukemia--in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Which immunization for children after chemotherapy?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Re-immunisations after childhood leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Do we really know which pediatric cancer patients need revaccination?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Recovery of blood B-lymphocytes and serum immunoglobulins after chemotherapy for childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Tetanus immunity in patients with hematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Risk of Haemophilus influenzae type b disease in children with cancer and response of immunocompromised leukemic children to a conjugate vaccine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Immunization of leukemic children with Haemophilus conjugate vaccine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Vaccination of children during treatment for leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Response of immunocompromised children with solid tumors to a conjugate vaccine for Haemophilus influenzae type b

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Antibody response to immunization with Haemophilus influenzae type b polysaccharide vaccine in children with cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Measles and rubella antibody status in previously vaccinated children with cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Decline in rates of seropositivity for measles, mumps, and rubella antibodies among previously immunized children treated for acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Immune Deficiencies following Cancer Treatment in Children

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Impact of conventional chemotherapy on levels of antibodies against vaccine-preventable diseases in children treated for cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Humoral immunity against diphtheria, tetanus and poliomyelitis after antineoplastic therapy in children and adolescents--a retrospective analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Immunodeficiency in long-term survivors of acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Use of licensed vaccines for active immunization of the immunocompromised host

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404326

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404326

1 reference

Dimensions Publication ID

14 August 2017

0 references

1 reference